bioMérieux Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Pierre Boulud
Algemeen directeur
€2.5m
Totale compensatie
Percentage CEO-salaris | 25.7% |
Dienstverband CEO | 1.3yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 3.3yrs |
Gemiddelde ambtstermijn bestuur | 10yrs |
Recente managementupdates
Recent updates
Is bioMérieux (EPA:BIM) Using Too Much Debt?
Nov 01Is There An Opportunity With bioMérieux S.A.'s (EPA:BIM) 31% Undervaluation?
Oct 14bioMérieux S.A.'s (EPA:BIM) Popularity With Investors Is Under Threat From Overpricing
Sep 26bioMérieux S.A. (EPA:BIM) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Sep 08Return Trends At bioMérieux (EPA:BIM) Aren't Appealing
Aug 03bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
May 30Investors Met With Slowing Returns on Capital At bioMérieux (EPA:BIM)
Apr 18bioMérieux's (EPA:BIM) Conservative Accounting Might Explain Soft Earnings
Mar 31bioMérieux S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 17These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Mar 15bioMérieux S.A.'s (EPA:BIM) Price In Tune With Earnings
Jan 27bioMérieux (EPA:BIM) Has More To Do To Multiply In Value Going Forward
Jan 06A Look At The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 16These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Oct 23bioMérieux (EPA:BIM) Has Some Way To Go To Become A Multi-Bagger
Oct 05There May Be Reason For Hope In bioMérieux's (EPA:BIM) Disappointing Earnings
Sep 15Estimating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Jun 30Returns At bioMérieux (EPA:BIM) Appear To Be Weighed Down
Jun 09Is bioMérieux (EPA:BIM) Using Too Much Debt?
Mar 31The Return Trends At bioMérieux (EPA:BIM) Look Promising
Feb 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jan 27bioMérieux (EPA:BIM) Has A Pretty Healthy Balance Sheet
Dec 16bioMérieux (EPA:BIM) Ticks All The Boxes When It Comes To Earnings Growth
Oct 18Is bioMérieux (EPA:BIM) Using Too Much Debt?
Sep 14Investors Should Be Encouraged By bioMérieux's (EPA:BIM) Returns On Capital
Aug 11An Intrinsic Calculation For bioMérieux S.A. (EPA:BIM) Suggests It's 20% Undervalued
Jul 23Do bioMérieux's (EPA:BIM) Earnings Warrant Your Attention?
Jul 05bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
May 26Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
May 11bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
Apr 23bioMérieux (EPA:BIM) Has Announced That It Will Be Increasing Its Dividend To €0.85
Apr 09bioMérieux's (EPA:BIM) Dividend Will Be Increased To €0.85
Mar 25Does bioMérieux (EPA:BIM) Have A Healthy Balance Sheet?
Mar 13I Ran A Stock Scan For Earnings Growth And bioMérieux (EPA:BIM) Passed With Ease
Feb 08Why We Like The Returns At bioMérieux (EPA:BIM)
Dec 21Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Dec 07Here's Why We Think bioMérieux (EPA:BIM) Is Well Worth Watching
Nov 07Is bioMérieux (EPA:BIM) A Risky Investment?
Oct 07Investors Shouldn't Overlook bioMérieux's (EPA:BIM) Impressive Returns On Capital
Sep 22Estimating The Fair Value Of bioMérieux S.A. (EPA:BIM)
Sep 07Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Aug 06There's Been No Shortage Of Growth Recently For bioMérieux's (EPA:BIM) Returns On Capital
Jun 15A Look At The Fair Value Of bioMérieux S.A. (EPA:BIM)
May 31Here's Why I Think bioMérieux (EPA:BIM) Might Deserve Your Attention Today
Apr 30bioMérieux (EPA:BIM) Could Easily Take On More Debt
Mar 28The Trend Of High Returns At bioMérieux (EPA:BIM) Has Us Very Interested
Mar 13Calculating The Intrinsic Value Of bioMérieux S.A. (EPA:BIM)
Feb 25If You Had Bought bioMérieux (EPA:BIM) Shares Five Years Ago You'd Have Earned 237% Returns
Feb 09If You Like EPS Growth Then Check Out bioMérieux (EPA:BIM) Before It's Too Late
Jan 20Could The Market Be Wrong About bioMérieux S.A. (EPA:BIM) Given Its Attractive Financial Prospects?
Dec 30These 4 Measures Indicate That bioMérieux (EPA:BIM) Is Using Debt Reasonably Well
Dec 17Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | €411m |
Mar 31 2024 | n/a | n/a | €384m |
Dec 31 2023 | €2m | €631k | €358m |
Sep 30 2023 | n/a | n/a | €372m |
Jun 30 2023 | n/a | n/a | €386m |
Mar 31 2023 | n/a | n/a | €419m |
Dec 31 2022 | €2m | €510k | €452m |
Sep 30 2022 | n/a | n/a | €502m |
Jun 30 2022 | n/a | n/a | €552m |
Mar 31 2022 | n/a | n/a | €577m |
Dec 31 2021 | €2m | €510k | €601m |
Sep 30 2021 | n/a | n/a | €555m |
Jun 30 2021 | n/a | n/a | €509m |
Mar 31 2021 | n/a | n/a | €457m |
Dec 31 2020 | €1m | €497k | €404m |
Compensatie versus markt: De totale vergoeding ($USD 2.55M ) Pierre } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 4.58M ).
Compensatie versus inkomsten: De vergoeding van Pierre is het afgelopen jaar met meer dan 20% gestegen.
CEO
Pierre Boulud (53 yo)
1.3yrs
Tenure
€2,452,864
Compensatie
Mr. Pierre Boulud is Chief Executive Officer of bioMérieux S.A. from July 01, 2023. He served as Chief Operating Officer of Clinical Operations at BioMérieux S.A. until 2023 and served as its Chief Operati...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chief Executive Officer | 1.3yrs | €2.45m | geen gegevens | |
Executive VP of Purchasing and Information Systems & CFO | 6.7yrs | geen gegevens | geen gegevens | |
Investor Relations | no data | geen gegevens | geen gegevens | |
Executive Vice President of Legal | 1.8yrs | geen gegevens | geen gegevens | |
Executive Vice President of Human Resources | 5.8yrs | geen gegevens | geen gegevens | |
Executive Vice President of Global Quality | 6.7yrs | geen gegevens | geen gegevens | |
Executive Vice President of Industrial Applications | 6.7yrs | geen gegevens | geen gegevens | |
Head of CSR | 4.8yrs | €21.99k | geen gegevens | |
Executive Vice President of Clinical Operations | 1.3yrs | geen gegevens | geen gegevens | |
Executive VP & Chief Medical Officer | less than a year | geen gegevens | geen gegevens | |
Executive Vice President of Research & Development | less than a year | geen gegevens | geen gegevens | |
Director of Investor Relations | no data | geen gegevens | geen gegevens |
3.3yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van BIM wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Founding Chairman | 7.3yrs | geen gegevens | geen gegevens | |
Non-Independent Director | 18.2yrs | €52.00k | 0.051% € 5.9m | |
Non-Independent Director | 14.4yrs | €61.00k | 0.000030% € 3.5k | |
Chairman | 20.6yrs | €1.92m | 0.000050% € 5.8k | |
Independent Director | 12.5yrs | €56.00k | 0.00013% € 15.1k | |
Independent Director | 12.5yrs | €44.00k | 0.000050% € 5.8k | |
Independent Director | 7.5yrs | €61.17k | 0.000030% € 3.5k | |
Independent Director | less than a year | geen gegevens | geen gegevens | |
Independent Director | 7.3yrs | €35.00k | 0.00015% € 17.5k | |
Employee Representative Director | 2.5yrs | €52.00k | geen gegevens |
10.0yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van BIM zijn ervaren en ervaren (gemiddelde ambtstermijn van 10 jaar).